FDA pulls opioid from market over misuse concernsBMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j2860 (Published 13 June 2017) Cite this as: BMJ 2017;357:j2860
- Owen Dyer
The US Food and Drug Administration has asked Endo Pharmaceuticals to withdraw its Opana ER formulation of oxymorphone amid concerns over a mounting epidemic of opioid misuse. It is the first time the FDA has made such a request, which could require court action to enforce.
The Dublin based drug manufacturer did not immediately say whether it would comply. Endo said in a statement that it is “reviewing the request and is evaluating the full range of potential options.”
The FDA’s request sent Endo’s shares tumbling 13.4% on Wall Street. The request was foreshadowed in March, when an FDA …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial